PMID- 10614526
OWN - NLM
STAT- MEDLINE
DCOM- 20000203
LR  - 20191024
IS  - 0391-4097 (Print)
IS  - 0391-4097 (Linking)
VI  - 22
IP  - 10
DP  - 1999 Nov
TI  - AlphaANP, AVP, and pituitary-thyroid axis in patients with congestive heart 
      failure and acute respiratory failure.
PG  - 766-71
AB  - The pituitary-thyroid axis and neurohumoral activation indexes were 
      simultaneously investigated in 16 in-patients hospitalized for cardiac heart 
      failure (CHF), New York Heart Association (NYHA), class II-IV, and Killip 
      clinical scale, class II-III, to evaluate their relationship with CHF morbidity 
      and the relative prognostic value. At entry the patients were divided into two 
      subgroups (A and B), according to the severity of CHF. Patients were further 
      classified into two subgroups, according to the subsequent clinical course (C, 
      poor outcome and D, improved clinical course). Blood samples were obtained every 
      day for the radioimmunoassay measurement of plasma alpha-atrial natriuretic 
      peptide (alphaANP), arginine vasopressin (AVP), and thyroid hormones, and the 
      results were compared with those of 12 control subjects. At admission, alphaANP 
      and 3,3',5'-triiodothyronine (rT3) values were higher, while 
      3,3',5-triiodothyronine (T3) to rT3 (T3/rT3) ratio was lower in subgroups A and B 
      than in controls (p<0.001), respectively, and in C than in D (p<0.001), 
      respectively, according to the prognosis. Conversely, no differences in other 
      thyroid indexes, nor a significant correlation between alphaANP and either rT3 or 
      T3/rT3 ratio were present in any of the subgroups. AVP plasma levels in subgroup 
      A were not statistically different from those of controls, whereas they were 
      significantly decreased in subgroups B and C (p<0.05) and D (p<0.001). In 
      conclusion, these results indicate that in CHF the pituitary-thyroid axis is not 
      altered, that alphaANP and T3/rT3 ratio are non-invasive and reliable predictors 
      of severity and prognosis, while AVP might be affected by the different 
      pathological processes leading to CHF or by the concomitant use of drugs.
FAU - Savastano, S
AU  - Savastano S
AD  - Cattedra di Endocrinologia, Dipartimento di Endocrinologia e Oncologia Molecolare 
      e Clinica, Napoli, Italy.
FAU - Cannavale, V
AU  - Cannavale V
FAU - Valentino, R
AU  - Valentino R
FAU - Tommaselli, A P
AU  - Tommaselli AP
FAU - Rossi, R
AU  - Rossi R
FAU - Luciano, A
AU  - Luciano A
FAU - Tauchmanova, L
AU  - Tauchmanova L
FAU - Mariano, A
AU  - Mariano A
FAU - Mazzitelli, L
AU  - Mazzitelli L
FAU - Macchia, V
AU  - Macchia V
FAU - Lombardi, G
AU  - Lombardi G
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 113-79-1 (Arginine Vasopressin)
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
MH  - Acute Disease
MH  - Aged
MH  - Aged, 80 and over
MH  - Arginine Vasopressin/*blood
MH  - Atrial Natriuretic Factor/*blood
MH  - Female
MH  - Follow-Up Studies
MH  - Heart Failure/complications/*physiopathology
MH  - Hospitalization
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pituitary Gland/*physiopathology
MH  - Prognosis
MH  - Respiratory Insufficiency/complications/*physiopathology
MH  - Thyroid Function Tests
MH  - Thyroid Gland/*physiopathology
EDAT- 1999/12/30 00:00
MHDA- 1999/12/30 00:01
CRDT- 1999/12/30 00:00
PHST- 1999/12/30 00:00 [pubmed]
PHST- 1999/12/30 00:01 [medline]
PHST- 1999/12/30 00:00 [entrez]
AID - 10.1007/BF03343642 [doi]
PST - ppublish
SO  - J Endocrinol Invest. 1999 Nov;22(10):766-71. doi: 10.1007/BF03343642.